1887

Abstract

Cryptococcal meningitis is a dreadful opportunistic fungal infection amongst human immunodeficiency virus (HIV)-infected patients. One complication in the management of the disease is the possible infection of a patient by two or more different strains of Cryptococcus neoformans. This study investigated the intra-individual genetic diversity and antifungal susceptibility of C. neoformans isolates from Yaoundé (Cameroon) HIV-infected patients with cryptococcal meningitis. Twenty-five clinical isolates were obtained during a prospective study. Five colonies were randomly collected from each initial sample. The 150 isolates obtained (125 colonies and 25 initial samples) were submitted to serotyping by multiplex PCR. Genotyping analyses were achieved using RFLP, and minisatellite- and microsatellite-length polymorphism. The antifungal susceptibility testing was carried out using a Sensititre YeastOne kit. Seven antifungals were tested: itraconazole, fluconazole, amphotericin B, ketoconazole, 5-fluorocytosine, posaconazole and voriconazole. The 150 isolates were identified as C. neoformans serotype A and genotype VNI. The microsatellite and minisatellite sequence analyses generated 15 genotypes. Six out of 25 (24 %) patients were found to be infected by two different genotypes. Antifungal susceptibility showed several profiles: posaconazole (0.015–0.25 µg ml), amphotericin B (0.06–1 µg ml), fluconazole (0.5–16 µg ml), itraconazole (0.008–0.12 µg ml), ketoconazole (0.008–0.12 µg ml), 5-fluorocytosine (0.25–16 µg ml) and voriconazole (0.008–0.12 µg ml). It was noted that isolates from the same patient might present different susceptibility profiles to an antifungal drug with differences of more than four dilutions. The results achieved highlighted the possible presence of isolates with different genotypes in a patient with dissimilar antifungal susceptibility profiles during a single episode of cryptococcal meningitis.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000265
2016-07-01
2019-10-20
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/7/579.html?itemId=/content/journal/jmm/10.1099/jmm.0.000265&mimeType=html&fmt=ahah

References

  1. Aller A. I., Martin-Mazuelos E., Lozano F., Gomez-Mateos J., Steele-Moore L., Holloway W. J., Gutierrez M. J., Recio F. J., Espinel-Ingroff A..( 2000;). Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. . Antimicrob Agents Chemother44:1544–1548. [CrossRef]
    [Google Scholar]
  2. Bertout S., Drakulovski P., Kouanfack C., Krasteva D., Ngouana T., Dunyach-Rémy C., Dongtsa J., Aghokeng A., Delaporte E. et al.( 2013;). Genotyping and antifungal susceptibility testing of Cryptococcus neoformans isolates from Cameroonian HIV-positive adult patients. . Clin Microbiol Infect19:763–769. [CrossRef][PubMed]
    [Google Scholar]
  3. Carvalho V. G., Terceti M. S., Dias A. L., Paula C. R., Lyon J. P., de Siqueira A. M., Franco M. C..( 2007;). Serotype and mating type characterization of Cryptococcus neoformans by multiplex PCR. . Rev Inst Med Trop Sao Paulo49:207–210. [CrossRef][PubMed]
    [Google Scholar]
  4. Casadevall A..( 2010;). Cryptococci at the brain gate: break and enter or use a Trojan horse?. J Clin Invest120:1389–1392. [CrossRef][PubMed]
    [Google Scholar]
  5. Chen Y., Litvintseva A. P., Frazzitta A. E., Haverkamp M. R., Wang L., Fang C., Muthoga C., Mitchell T. G, Perfect J. R..( 2015;). Comparative analyses of clinical and environmental populations of Cryptococcus neoformans in Botswana. . Mol Ecol24:3559–3571. [CrossRef][PubMed]
    [Google Scholar]
  6. Cogliati M..( 2013;). Global molecular epidemiology of Cryptococcus neoformans and Cryptococcus gattii : an atlas of the molecular types. . Scientifica2013:1–23. [CrossRef]
    [Google Scholar]
  7. Cogliati M., Zamfirova R. R., Tortorano A. M., Viviani M. A..the Fimua Cryptococcosis Network( 2013;). Molecular epidemiology of Italian clinical Cryptococcus neoformans var. grubii isolates . . Med Mycol51:499–506. [CrossRef][PubMed]
    [Google Scholar]
  8. Desnos-Ollivier M., Patel S., Spaulding A. R., Charlier C., Garcia-Hermoso D., Nielsen K., Dromer F..( 2010;). Mixed infections and evolution in the human fungal pathogen Cryptococcus neoformans . . MBio1:e00091-10. [CrossRef]
    [Google Scholar]
  9. Desnos-Ollivier M., Patel S., Raoux-Barbot D., Heitman J., Dromer F..French Cryptococcosis Study Group( 2015;). Cryptococcosis serotypes impact outcome and provide evidence of Cryptococcus neoformans speciation. . MBio6:e00311-15. [CrossRef][PubMed]
    [Google Scholar]
  10. Espinel-Ingroff A., Aller A. I., Canton E., Castanon-Olivares L. R., Chowdhary A., Cordoba S., Cuenca-Estrella M., Fothergill A., Fuller J. et al.( 2012a;). Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. . Antimicrob Agents Chemother56:5898–5906. [CrossRef]
    [Google Scholar]
  11. Espinel-Ingroff A., Chowdhary A., Cuenca-Estrella M., Fothergill A., Fuller, Hagen F., Govender N., Guarro J., Johnson E. et al.( 2012b;). Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for amphotericin B and flucytosine. . Antimicrob Agents Chemother56:3107–3113. [CrossRef]
    [Google Scholar]
  12. Hagen F., Illnait-Zaragozí M. T., Meis J. F., Chew, Curfs-Breuker I., Mouton J. W., Hoepelman, Spanjaard L., Verweij P. E. et al.( 2012;). Extensive genetic diversity within the Dutch clinical Cryptococcus neoformans population. . J Clin Microbiol50:1918–1926. [CrossRef][PubMed]
    [Google Scholar]
  13. Hagen F., Khayhan K., Theelen B., Kolecka A., Polacheck I., Sionov E., Falk R., Parnmen S., Lumbsch H. T , Boekhout T..( 2015;). Recognition of seven species in the Cryptococcus gattii/Cryptococcus neoformans species complex. . Fungal Genet Biol78:16–48. [CrossRef][PubMed]
    [Google Scholar]
  14. Illnait-Zaragozi M.-T., Martínez-Machín G. F., Fernández-Andreu C. M., Boekhout T., Meis J. F., Klaassen C. H..( 2010a;). Microsatellite typing of clinical and environmental Cryptococcus neoformans var. grubii isolates from Cuba shows multiple genetic lineages. . PLoS One5:e9124. [CrossRef]
    [Google Scholar]
  15. Illnait-Zaragozí M.-T., Martínez-Machín G. F., Fernández-Andreu C. M., Hagen F., Boekhout T., Klaassen C. H., Meis J. F..( 2010b;). Microsatellite typing and susceptibilities of serial Cryptococcus neoformans isolates from Cuban patients with recurrent cryptococcal meningitis. . BMC Infect Dis10:289–295. [CrossRef][PubMed]
    [Google Scholar]
  16. Ito-Kuwa S., Nakamura K., Aoki S., Vidotto V..( 2007;). Serotype identification of Cryptococcus neoformans by multiplex PCR. . Mycoses50:277–281. [CrossRef][PubMed]
    [Google Scholar]
  17. Jain N., Wickes B. L., Keller S. M., Fu J., Casadevall A., Jain P., Ragan M. A., Banerjee U., Fries B. C..( 2005;). Molecular epidemiology of clinical Cryptococcus neoformans strains from India. . J Clin Microbiol43:5733–5742. [CrossRef][PubMed]
    [Google Scholar]
  18. Kaocharoen S., Ngamskulrungroj P., Firacative C., Trilles L., Piyabongkarn D., Banlunara W., Poonwan N., Chaiprasert A., Meyer W. et al.( 2013;). Molecular epidemiology reveals genetic diversity amongst isolates of the Cryptococcus neoformans/C. gattii species complex in Thailand. . PLoS Negl Trop Dis7:e2297. [CrossRef][PubMed]
    [Google Scholar]
  19. Kronstad J. W., Attarian R., Cadieux B., Choi J., D'Souza C. A., Griffiths E. J., Geddes J. M., Hu G., Jung W. H. et al.( 2011;). Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. . Nat Rev Microbiol9:193–203. [CrossRef][PubMed]
    [Google Scholar]
  20. Lahuerta M., Ue F., Hoffman S., Elul B., Kulkarni S. G., Wu Y., Nuwagaba-Biribonwoha H., Remien R. H., El Sadr W. et al.( 2013;). The problem of late ART initiation in sub-Saharan Africa: a transient aspect of scale-up or a long-term phenomenon?. J Health Care Poor Underserved24:359–383. [CrossRef][PubMed]
    [Google Scholar]
  21. Litvintseva A. P., Kestenbaum L., Vilgalys R., Mitchell T. G..( 2005;). Comparative analysis of environmental and clinical populations of Cryptococcus neoformans . . J Clin Microbiol43:556–564. [CrossRef][PubMed]
    [Google Scholar]
  22. Maslin J., Morand J. J., Menard G., Camparo P..( 2002;). Les cryptococcoses. . Med Trop62:480–484.
    [Google Scholar]
  23. Mdodo R., Moser S. A., Jaoko W., Baddley J., Pappas P., Kempf M. C., Aban I., Odera S., Jolly P..( 2011;). Antifungal susceptibilities of Cryptococcus neoformans cerebrospinal fluid isolates from AIDS patients in Kenya. . Mycoses54:e438e442. [CrossRef][PubMed]
    [Google Scholar]
  24. Meyer W., Castañeda A., Jackson S., Huynh M., Castañeda E..IberoAmerican Cryptococcal Study Group( 2003;). Molecular typing of IberoAmerican Cryptococcus neoformans isolates. . Emerg Infect Dis9:189–195. [CrossRef][PubMed]
    [Google Scholar]
  25. Meyer W., Aanensen D. M., Boekhout T., Cogliati M., Diaz M. R., Esposto M. C., Fisher M., Gilgado F., Hagen F. et al.( 2009;). Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii . . Med Mycol47:561–570. [CrossRef][PubMed]
    [Google Scholar]
  26. O'Meara T. R., Holmer S. M., Selvig K., Dietrich F., Alspaugh J. A..( 2013;). Cryptococcus neoformans Rim101 is associated with cell wall remodeling and evasion of the host immune responses. . MBio4:e00522-12. [CrossRef][PubMed]
    [Google Scholar]
  27. Park B. J., Wannemuehler K. A., Marston B. J., Govender N., Pappas P. G., Chiller T. M..( 2009;). Estimation of the current global burden of cryptococcal meningitis among persons living with HIV/AIDS. . AIDS23:525–530. [CrossRef][PubMed]
    [Google Scholar]
  28. Pfaller M. A., Castanheira M., Diekema D. J., Messer S. A., Jones R. N..( 2011;). Wild-type MIC distributions and epidemiologic cutoff values for fluconazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. . Diagn Microbiol Infect Dis71:252–259. [CrossRef][PubMed]
    [Google Scholar]
  29. Qiu J., Olszewski M. A., Williamson P. R., Jin Q..( 2013;). Cryptococcus neoformans growth and protection from innate immunity are dependent on expression of a virulence-associated DEAD-box protein, Vad1. . Infect Immun81:777–788. [CrossRef][PubMed]
    [Google Scholar]
  30. Thompson G. R., Wiederhold N. P., Fothergill A. W., Vallor A. C., Wickes B. L., Patterson T. F..( 2009;). Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans . . Antimicrob Agents Chemother53:309–311. [CrossRef][PubMed]
    [Google Scholar]
  31. Trilles L., Lazéra M. S., Wanke B., Oliveira R. V., Barbosa G. G., Nishikawa M. M., Morales B. P., Meyer W..( 2008;). Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. . Mem Inst Oswaldo Cruz103:455–462. [CrossRef][PubMed]
    [Google Scholar]
  32. Trilles L., Meyer W., Wanke B., Guarro J., Lazéra M..( 2012;). Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. . Med Mycol50:328–332. [CrossRef][PubMed]
    [Google Scholar]
  33. UNAIDS( 2013;). Rapport Mondial: Rapport ONUSIDA sur L’épidémie Mondiale de Sida. Geneva:: UNAIDS;.
    [Google Scholar]
  34. WHO( 2011;). Rapid Advice: Diagnosis, Prevention and Management of Cryptococcal Disease in HIV-Infected Adults, Adolescents and Children. . Geneva: World Health Organization http://whqlibdoc.who.int/publications/2011/9789241502979_eng.pdf.
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000265
Loading
/content/journal/jmm/10.1099/jmm.0.000265
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error